NEW YORK (GenomeWeb News) — Millipore yesterday said first-quarter revenues increased 39 percent as R&D spending rose 50 percent and profit slid 23 percent.
 
Total receipts for the three months ended March 31 increased to $372 million from $268.4 million year over year.
 
Sales in the company’s Bioprocess segment rose 40 percent to $214.3 million, while Bioscience revenue swelled 51 percent to $157.7 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.